<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511379</url>
  </required_header>
  <id_info>
    <org_study_id>EXJ821-P001 (C-13-039)</org_study_id>
    <secondary_id>CTRI/2015/10/006320</secondary_id>
    <nct_id>NCT02511379</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Systane速 Balance in Dry Eye Subjects</brief_title>
  <official_title>Clinical Evaluation of Systane速 Balance on Corneal Staining in Indian Subjects With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Systane速 Balance
      following 90 days of QID (4 times/day) dosing among Indian subjects with dry eye. This study
      will be conducted in India.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Management decision
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Corneal Staining Score at all study time points</measure>
    <time_frame>Baseline (Day 0), Up to Day 90</time_frame>
    <description>Corneal staining will be assessed by the Investigator through slit-lamp examination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Systane Balance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propylene Glycol 0.6% eye drops</intervention_name>
    <arm_group_label>Systane Balance</arm_group_label>
    <other_name>Systane速 Balance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign informed consent and willing and able to attend all study visits;

          -  Dry eye in both eyes diagnosed by an ophthalmologist;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential who are pregnant or breastfeeding;

          -  Any medical condition (systemic or ophthalmic) that may preclude the safe
             administration of test article or safe participation in the study;

          -  Ocular surgery or ocular trauma requiring medical or pharmacological treatment within
             1 year of Screening;

          -  Use of topical ocular prescription or non-prescription medications, RESTASIS or
             topical ocular steroids within 14 days of Screening;

          -  Use of any artificial tears/gels/lubricants/rewetting drops within 4 hours of
             Screening;

          -  Contact lens wear within 1 week of Screening and/or unwillingness to discontinue
             contact lens wear for the duration of the study;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head CTM, Med Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Laboratories Pvt Ltd (India)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon India for Trial Locations</name>
      <address>
        <city>Bangalore</city>
        <state>Kamataka</state>
        <zip>560048</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 15, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

